Could some breast cancer patients skip surgery? new trial investigates

NCT ID NCT07357948

Not yet recruiting Disease control Sponsor: Institut Curie Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether women with triple-negative breast cancer who have a complete response to chemo-immunotherapy can safely skip breast and lymph node surgery. Half of the 150 participants will receive standard care including surgery, while the other half will have no surgery. The goal is to see if avoiding surgery leads to similar cancer control with fewer side effects and better quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: omission of surgery
What this could lead to: If successful, this could allow some women with triple-negative breast cancer to avoid surgery after chemo-immunotherapy, reducing complications and improving quality of life while maintaining cancer control.
What could go wrong: This is a phase 2 trial with only 150 participants, so results are preliminary. Skipping surgery might increase the risk of cancer returning in the breast or lymph nodes, and the approach may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-METASTATIC TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Locations

Centre Georges-François Leclerc

Dijon, 21000, France
Hôpital Tenon

Paris, 75020, France
Institut Curie Saint-Cloud

Saint-Cloud, 92210, France
Institut Curie-Paris

Paris, 75005, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.